• Citer

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

par Debien, Véronique;Marta, Guilherme Nader;Agostinetto, Elisa;Sirico, Marianna;Jacobs, Flavia;Molinelli, Chiara;Moreau, Michel ;Paesmans, Marianne ;De Giorgi, Ugo;Santoro, Armando;Taylor, Donatienne;Duhoux, Francois F.P.;Botticelli, Andrea;Barchiesi, Giacomo;Speranza, Iolanda;Lambertini, Matteo Md Phd M.;Wildiers, Hans;de Azambuja, Evandro ;Piccart-Gebhart, Martine
Référence Critical reviews in oncology/hematology, 190, 104089
Publication Publié, 2023-10-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Up to 20% of breast cancer overexpress HER2 protein, making it a reliable target for antibody-based treatments. In early HER2-positive breast cancer avoiding anthracycline-based chemotherapy is a challenge. Based on the single-arm phase II APT trial results, adjuvant paclitaxel/trastuzumab is an accepted regimen for patients with stage I HER2-positive disease. In our retrospective study of 240 patients, the median tumor size was 12.0 mm (IQR 9 −15), and 204 (85%) had estrogen receptor-positive disease. After a median follow-up of 4.6 years, 3-year real-world disease-free survival, distant DFS, and overall survival were 98.8% (95% confidence interval (CI), 96.2–99.6), 99.2% (95% CI, 96.7–99.8), and 98.3% (95% CI, 96.2–99.6), respectively. In a real-world setting, an adjuvant paclitaxel/trastuzumab regimen was associated with low recurrence rates among women with stage I, HER2-positive breast cancer. Additionally, we reviewed other treatment optimization strategies attempted or ongoing in HER2-positive breast cancer.